Brain Tumour Support NZ welcomes the announcement today
from Associate Health Minister David Seymour that promises
to speed up Medsafe’s approval process for new
medicines.
The new rule, known as the “Rule of
Two”, allows Medsafe to approve new medicines within 30
days if that medicine has already been approved by two
recognised jurisdictions. Such jurisdictions will initially
include Australia, the United States, Canada, the United
Kingdom, the European Union, Singapore and
Switzerland.
Chief Executive of Brain Tumour Support
NZ, Sarah Verran, said that the Rule of Two will provide
meaningful benefits to brain tumour patients, especially
those with highly malignant tumours for which there is
currently no cure, by bringing them to market
sooner.
“Sadly, brain cancers often
don’t respond to traditional treatments like surgery,
radiation or chemotherapy, which means the only hope for
these patients are new targeted treatments, such as
immunotherapies or cell based therapies”, Sarah
said.
“New Zealand is typically at the
end of the queue when it comes to new medicine approvals,
with the US, UK and Australia approving medicines months or
years faster than New Zealand. Brain tumour patients can’t
wait months or years for these medicines, they need them
today,” Sarah said.
She emphasised that Medsafe
approval is only the first step in obtaining widespread
access to new medicines, which often come with a hefty price
tag. Following Medsafe registration, the medicines must
still be funded by Pharmac before being affordable for most
patients.
Advertisement – scroll to continue reading
Sarah cites the example of bevacizumab,
which was approved by Medsafe to treat brain cancer in 2009,
and for which patients are still fighting for access to 16
years on.
While praising the Rule of Two as a step in
the right direction, Brain Tumour Support NZ is seeking
further reforms to speed up the registration process for new
medicines, especially those being developed for rare cancers
and disorders such as brain tumours.
“Many
pharmaceutical companies are slow to register their products
in New Zealand. They regard us as a small market and a tough
market in which to gain reimbursement (from Pharmac),”
according to Sarah.
“We believe Medsafe should
instigate schemes such as an Orphan Drug Designation, as
many other countries have, which offer incentives for
companies to register their products here. Such incentives
could include an exemption of registration fees or extended
patent protection,” she said.
“A simpler, faster
registration process such as that promised by the Rule of
Two is a fantastic start and we’re encouraged by the
current government’s ongoing commitment to streamline
access to new medicines for the benefit of all New
Zealanders.”
ABOUT BRAIN
TUMOURS
• Around 350 New Zealanders
are diagnosed with primary brain cancer each year
representing 1.4% of all cancers diagnosed. Many more
are diagnosed with secondary, or metastatic, brain tumours
(cancers which have spread to the brain from elsewhere
in the body).
• The 5 year survival rate for
glioblastoma, the most common type of brain cancer in
adults, is just 5%. Survival rates for brain cancer
have not improved significantly in the last 30
years.
• Around 260 New Zealanders die each
year from brain cancer, making it the 10th most fatal
cancer. • Brain cancer is the biggest cancer killer of
children in New Zealand, being responsible for 42% of
all childhood cancer deaths (almost double that of
leukaemia).
• Brain tumours can affect anyone,
of any ethnicity, and at any age. The causes of most brain
tumours are unknown so prevention and screening are
not possible.
Website:
www.braintumoursupport.org.nz
© Scoop Media



















Discussion about this post